Breast Cancer Now media statements
We respond to the Scottish Medicines Consortium (SMC) decision to approve olaparib (Lynparza) for use on the NHS in Scotland for certain patients
Claire Rowney, Chief Executive at Breast Cancer Now, said:
Breast Cancer Now responds to being beneficiary of Sir Chris Hoy's Tour de 4
Responding to news released that Sir Chris Hoy has launched a new Tour de 4 cycling challenge, taking place on Sunday 7 September 2025 at th...
Responding to the Department of Health and Social Care’s plans to launch a world-leading trial to test how cutting-edge AI tools can be used to catch breast cancer cases earlier
Breast Cancer Now’s chief executive, Claire Rowney, said:
Breast Cancer Now responds to announcement of re-launch of cancer plan and consultation opening
Claire Rowney, chief executive at Breast Cancer Now, said:
Breast Cancer Now response to the death of Linda Nolan
Claire Rowney, CEO, Breast Cancer Now says:
We respond to The NHS Jewish BRCA Testing Programme identifying 235 people with higher risk of cancer
Claire Rowney, chief executive of Breast Cancer Now, said:
We respond to NICE’s provisional rejection of capivasertib with fulvestrant for certain types of secondary breast cancer
Claire Rowney, chief executive of Breast Cancer Now, said:
We respond to Audit Wales Cancer Services Report
Claire Rowney, chief executive, at Breast Cancer Now, said:
Responding to the NICE decision to approve olaparib (Lynparza) for certain people with locally advanced or secondary breast cancer who have inherited an altered BRCA gene.
Responding, Claire Rowney, chief executive at Breast Cancer Now, said:
We respond to new University of Oxford research highlighting the potential of the TriOx test to improve early cancer detection
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said:
Breast Cancer Now responds to early diagnosis in England reaching highest level ever
In response to figures showing early cancer diagnosis in England reaching highest ever level, Claire Rowney, chief executive of Breast Cance...
Breast Cancer Now 's response to NICE final decision on elacestrant (Korserdu)
Responding, Claire Rowney, chief executive at Breast Cancer Now, said: